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Edited by Veli-Pekka LehtoAbstract The nuclear receptor coactivator RAC3 plays impor-
tant roles in many biological processes and tumorigenesis. We
found that RAC3 is over-expressed in human chronic myeloid
leukemia cells K562, which are normally resistant to TRAIL-
induced apoptosis. RAC3 down-regulation by siRNA rendered
these cells sensitive to TRAIL-induced cell death. In addition
to the up-regulation of TRAIL receptors, the process involves
Bid, caspases and PARP activation, loss of mitochondrial mem-
brane potential, and release of AIF, cytochrome c and Smac/
DIABLO to the cytoplasm. We conclude that RAC3 is required
for TRAIL resistance and that this anti-apoptotic function is
independent of its role in hormone receptor signaling.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The steroid receptor coactivator SRC/p160 family (SRC-1/
NCoA1; SRC-2/TIF2/GRIP-1; SRC-3/p/CIP/RAC3/ACTR/
AIB-1/TRAM-1) interacts with nuclear receptors (NRs) and
enhance their transactivation in a ligand-depend manner
[1,2]. Two members of SRC family, SRC-1 and receptor asso-
ciated coactivator-3 (RAC3), are also known to contain an
intrinsic histone acetyltransferase activity [3,4] and all p160
proteins can recruit other general coactivators with enzymatic
activity like CBP/p300, p/CAF, CARM-1 and PRMT1 [5],
required for chromatin remodelling. It has been suggested that
RAC3 could be more promiscuous than other p160 coactiva-
tors enhancing the transcription of non-NR proteins including
NF-jB [6] and CREB [7]. Moreover, we have previously
shown that RAC3 could be found associated with a protein
complex containing the estrogen receptor in addition to NF-Abbreviations: RAC3, receptor associated coactivator-3; TRAIL,
tumor necrosis factor (TNF)- related apoptosis-inducing ligand; FLIP,
FLICE inhibitory protein; AIF, apoptosis-inducing factor
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doi:10.1016/j.febslet.2007.09.052jB, that could regulate the expression of genes involved in cell
proliferation [8]. RAC3 gene is highly overexpressed in several
tumors, including breast and ovary tumors [9], endometrium
[10], gastric [11], hepatocellular carcinoma [12], and prostate
[13]. Its activity has been linked to proliferative processes
[14,15].
FasL, TNF-a and TRAIL [tumor necrosis factor (TNF)-
related apoptosis-inducing ligand] are ligands of a family of
receptors with death domains. The binding of these molecules
to their speciﬁc receptors causes, in responsive cells, the
receptor oligomerization and triggers the activation of the
cytoplasmic caspase machinery, resulting in disruption of
normal cellular and nuclear morphology followed by DNA
fragmentation [16]. TRAIL binds to ﬁve receptors: four of
which are membrane-bound and one soluble receptor [17].
Two of these receptors, death receptor 4 (DR4) and -5
(DR5) are agonistic receptors containing a cytoplasmic death
domain activated by TRAIL. Upon binding of TRAIL
homotrimer to DR4 or DR5, which induces trimerization
of the receptors, a death-inducing signaling complex (DISC)
is formed. The adaptor protein FADD is then recruited to
the complex, facilitating incorporation of the initiator procas-
pase-8 prodomain into the DISC. This leads to activation of
procaspase-8, a potent activator of downstream eﬀector casp-
ases e.g., caspase-3, -6, and -7 [17]. TRAIL is a potent indu-
cer of tumor-speciﬁc apoptosis in vitro and in vivo, which
appears to induce apoptosis preferentially in tumor cells ver-
sus normal cells. The resistance of cells to TRAIL seems to
be tightly regulated and dependent of the cell-type and the
cell-diﬀerentiation [18].
Because resistance to apoptosis causes the failure in leuke-
mia treatment, as in other tumor therapies, there is important
to ﬁnd the molecular mechanisms responsible of such re-
sponse, in order to enhance the sensitivity to pro-apoptotic sig-
nals. In this work, we provide evidence that human chronic
myeloid leukemia (CML) K562 cells express high levels of
the p160 coactivator RAC3 as compared with positive control
human breast tumor T-47D cells [19]. Moreover, RAC3 down-
regulation by siRNA sensitized K562 cells to activation of the
extrinsic/receptor-mediated cascade by TRAIL by inducing a
potent cell death signal through a mechanism involving en-
hanced expression of DR4/DR5, and activation of caspase cas-
cades and mitochondrial damage.
Therefore, our ﬁndings suggest that RAC3 is an interesting
molecule to be analyzed in several leukemic cells as a possible
anti-apoptotic mediator.blished by Elsevier B.V. All rights reserved.
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2.1. Cells and cell culture
K562 cells were obtained from American Type Culture Collection
(Manassas, VA) and cultured in RPMI 1640 supplemented with so-
dium pyruvate, MEM essential vitamins, L-glutamate, penicillin, strep-
tomycin, and 10% fetal bovine serum (Gibco, Invitrogen, Carlsbad,
CA). Human embryonic kidney HEK293 cells were grown in Dul-
becco’s modiﬁed Eagle’s medium High Glucose (DMEM) (Gibco Lab-
oratories, Grand Island, NY) supplemented with 10% FCS, penicillin
(100 U/ml) and streptomycin (100 mg/ml). The human breast tumor
T47D cells were grown in Dulbecco’s modiﬁed Eagle’s F12 medium
(DMEM-F12) (Gibco Laboratories) supplemented with 10% FCS,
penicillin (100 U/ml) and streptomycin (100 mg/ml). All the cells were
maintained in a 37 C, 5% CO2, fully humidiﬁed incubator. The pSi-
lencer-RAC3 small interfering RNA (siRNA) plasmid was prepared
using Ambion system following the manufacturer’s protocol according
to the previously reported sequence [14] and a control not speciﬁc siR-
NA was obtained from Dharmacon Research Inc.. K562 cells stably
over-expressing RAC3-siRNA and their control counterparts were se-
lected by sub-culturing the cells on selection medium containing G418
antibiotic (Invitrogen).2.2. Drugs and Chemicals
TRAIL/Apo2L was purchased from Alexis (Carlsbad, CA, USA)
and stored in aliquots at 80 C. Unless stated, reagents were obtained
from Sigma–Aldrich (St. Louis, MO), BD-Pharmingen (San Diego,
CA) or New England Nuclear (Boston, MA).2.3. Assessment of apoptosis
Apoptotic cells were evaluated by Annexin V/propidium iodide (BD
PharMingen) and 7-AAD staining, according to the manufacturer’s
instructions as previously described [20]. In these studies,
1–2 · 105 cells were harvested for each experimental condition. Analy-
sis was carried out using a Becton Dickinson FACScan cytoﬂuorome-
ter (Mansﬁeld, MA, USA). Morphologic assessment was evaluated by
Wright-Giemsa–stained cytospin preparations.2.4. Assessment of mitochondrial membrane potential (Dwm)
At the indicated intervals, cells were harvested and 2 · 105 cells were
incubated with 40 nmol/l of the lipophilic ﬂuorochrome DiOC6
(15 min, 37 C). Loss of mitochondrial membrane potential was deter-
mined by ﬂow cytometry as previously described [21].2.5. Analysis of cytosolic cytochrome c, Smac/DIABLO and apoptosis-
inducing factor (AIF)
A previously described technique was used to isolate the S-100 (cyto-
solic) cell fraction of treated cells [21]. For each condition, 30 lg of
protein isolated from the S-100 cell fraction were separated and de-
tected by Western blot as described.2.6. Western blot analysis
Whole-cell pellets were washed and resuspended in PBS, and lysed
with loading buﬀer (Invitrogen) as previously described [20]. Thirty
micrograms of total protein for each condition were separated by
4–12% bis-Tris NuPAge precast gel system (Invitrogen) and electro-
blotted to nitrocellulose. After incubation with the corresponding pri-
mary and secondary antibodies, blots were developed by enhanced
chemiluminescence (New England Nuclear).2.7. Antibodies for Western blot analysis
Primary antibodies for the following proteins were used at the des-
ignated dilutions: RAC3, TIF2 and SRC-1 (1:4000; Santa Cruz);
poly- (ADP)ribose polymerase (1:1000; BioMol, Plymouth Meeting,
PA); pro-caspase-3, cytochrome c and pro-caspase-9 (1:1000, BD-
PharMingen); procaspase-8 (1:2000; Alexia Corporations, San Diego,
CA); Bid (1:1000; Cell Signaling, Beverly, MA); tubulin (1:4000; Cal-
biochem, San Diego, CA); AIF and FLIP, (1:1000; Santa Cruz); Sec-
ondary antibodies conjugated to horseradish peroxidase were
obtained from Kirkegaard and Perry Laboratories Inc. (Gaithersburg,
MD).2.8. Surface expression analysis of DR4 and DR5
Cells (1 · 106) were washed two times with PBS and then incubated
with DR4 or DR5 speciﬁc antibodies conjugated with FITC (Alexis) in
PBS for 30 min at room temperature. After washing for three times,
cells were analyzed on FACScan ﬂow cytometer. Samples with an
unspeciﬁc mouse IgG1 antibody were used as a control.
2.9. Measurement of NF-jB activity
Nuclear protein was extracted using Nuclear Extract Kit (Active
Motif) and NF-jB activity was determined by using an enzyme linked
immunosorbent assay (ELISA) Kit TransAM NF-jB p65 Transcrip-
tion Factor Assay Kit (Active Motif), according to manufacturer’s
instructions. Brieﬂy, the activated form of NF-jB that is present in
nuclear extracts was detected by using an anti-p65 speciﬁc antibody
that recognizes the NF-jB bound to a consensus DNA oligonucleotide
immobilized in a 96-well plate. Addition of a secondary antibody con-
jugated to horseradish peroxidase provides sensitive colorimetric read-
out by spectrophotometry.
2.10. Statistical analysis
The signiﬁcance of diﬀerences between experimental conditions was
determined using ANOVA and Tukey–Kramer Multiple Comparisons
Test for unpaired observations.3. Results
3.1. RAC3 is over-expressed in K562 cells
RAC3 is over-expressed in several hormone-dependent and
–independent tumors [9–13]. To determine the protein levels
of p160 coactivator RAC3 in K562 cells, Western blot analysis
was performed comparing levels of this protein in human
HEK293 cell line which have almost undetectable nuclear
receptor coactivator levels (unpublished data), a positive con-
trol of RAC3 over-expression human breast cancer T47D cells
[19] and K562 cells. As shown in Fig. 1A, K562 cells displayed
higher levels of RAC3 than in normal HEK293 cells but sim-
ilar to the positive control T47D cells. In view of these obser-
vations and to investigate the role that RAC3 may play in
K562 cells sensitivity to a pro-apoptotic stimulus, stable
K562 clones expressing low levels of coactivator were gener-
ated. K562 cells were transfected with a vector carrying either
a control small interfering RNA (K562/con) or a RAC3 small
interfering RNA (siRNA) and two clones with diﬀerent RAC3
expression levels, i.e. a moderate expressing clone (#10) and a
very low expressing clone (#4) were selected (Fig. 1B). Impor-
tantly, RAC3 down-regulation did not aﬀect the protein levels
of the two other p160 coactivators, SRC-1 and TIF2 as previ-
ously described for this speciﬁc sequence of siRNA [14]
(Fig. 1B).
3.2. Loss of resistance to TRAIL-induced cell death by RAC3
down-regulation
To investigate the eﬀect ofRAC3down-regulation in TRAIL-
induced cell death, RAC3 siRNA clones and the wild-typeK562
cells were exposed to diﬀerent concentrations of TRAIL includ-
ing 10, 25, 75, 100 and 250 ng/ml.We observed that startingwith
TRAIL 25 ng/ml, RAC3 down regulation sensitized K562 cells
to TRAIL-induced apoptosis (Fig. 2A). For example, after
16 h treatment with TRAIL 25 ng/ml, while no diﬀerences were
observed in the percentage of apoptosis in K562/con (2.8%) or
the wild-type cells (2.9%), a marked increase was determined
in both RAC3 siRNA clones (i.e., 67.8% and 57.4%, low and
medium RAC3 clones, respectively; Fig. 2A). A time-course
analysis of TRAIL-induced lethality showed a rapid and signif-
Fig. 2. RAC3 down-regulation sensitivizes K562 cells to TRAIL-
induced apoptosis. (A) RAC3-siRNA clones #4 and #10, K562/wt and
K562/con cells were exposed to 25 ng/ml TRAIL for 16 h after which
cells were stained by 7-AAD and monitored for cell death by ﬂow
cytometry. (B) Time-course analysis of cell death induced by 25 ng/ml
TRAIL as determined by ﬂow cytometry analysis in RAC3-siRNA
clone #4, clone #10, K562/wt and K562/con cells. Cells were collected
at the indicated time-intervals (0–24 h) and stained with annexin V/PI.
Data shown represent the means ± S.D. from three independent
experiments. *, ** Signiﬁcantly higher than values determined in
K562 after 4 h exposure; P < 0.01 and <0.05, respectively.
Fig. 1. RAC3 is over-expressed in K562 human leukemia cells and its
down-regulation by siRNA does not modify p160 coactivators SRC-1
and TIF2 protein levels. (A) Western blot analysis of RAC3 in
HEK293, T47D, K562/wild-type and stably K562 RAC3-siRNA
transfected clones #4 and #10. (B) Western blot analysis of basal
p160 coactivators RAC3, SRC-1 and TIF2 in K562 cells stably
transfected with a RAC3-siRNA (clone #4 and #10) and the wild-type
cells. The results of a representative study are shown; two additional
experiments yielded similar results.
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(Fig. 2B). Interestingly, diﬀerences in apoptosis appeared depen-
dent on RAC3 expression levels, i.e. higher TRAIL-induced
lethality correlated with lower RAC3 levels, clearly indicating
that the presence or absence of RAC3 plays a critical role in
TRAIL-induced cell death.
3.3. RAC3 down-regulation inhibits NF-jB basal activity and
increases the sensitivity to TRAIL-induced activation
In previous studies we have demonstrated that RAC3 is a
NF-jB coactivator [6]. The anti-apoptotic role of this tran-
scription factor is well-known [22]. In order to determine
whether the NF-jB activity was aﬀected by RAC3 down-reg-
ulation, the levels of active nuclear NF-jB were analyzed by
ELISA. In these experiments, K562 wild-type, K562/con and
RAC3-siRNA #4 and #10 clones were stimulated during 1 h
with 25 ng/ml of TRAIL and then, the nuclear extracts were
analyzed. It is important to notice that K562 wild-type cells
are known to display high constitutive levels of NF-jB activity
associated with the expression of Bcr-Abl [23]. As shown in
Fig. 3, the basal NF-jB activity appeared signiﬁcantly inhib-
ited in RAC3-siRNA clones compared to K562/con and
K562/wt cells. Moreover, NF-jB activity was directly related
to the expression levels of RAC3 as signiﬁcant diﬀerences were
evident between medium and low expression in RAC3-siRNA
clones. Interestingly, upon TRAIL stimulation, RAC3-siRNA
clones displayed increased NF-jB activity to values compara-
ble to those of K562/con and K562/wt cells, which themselves
did not show signiﬁcant changes.
3.4. TRAIL-induced apoptosis in low level RAC3 cells involves
activation of both caspases and Bid and PARP cleavage
Western blot analysis of lysates obtained from RAC3-siR-
NA, K562/con and K562 wild-type cells exposed to 25 ng/mlof TRAIL during 8 and 16 h revealed that enhanced
TRAIL-mediated cell death in RAC3-siRNA #4 and #10
clones was accompanied by cleavage/activation of procaspase
8 and the caspase-8 substrate Bid as compared with K562/
con and K562/wt cells, where no changes were detected
(Fig. 4). In addition, activation of caspases-9 and -3 as well
as degradation of caspase-3 substrate poly ADP-ribose poly-
merase (PARP) were clearly observed in both RAC3-siRNA
clones; moreover, the level of caspases and Bid activation were
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Fig. 3. Modulation of NF-jB activity by RAC3 down-regulation and
TRAIL stimulation. K562/wt, K562/con and RAC3-siRNA cells were
treated with 25 ng/ml TRAIL for 1 h. Then, cells were collected,
nuclear extracts prepared and NF-jB activity was assessed by an
ELISA kit. Data shown represent the means ± S.D. from three
independent experiments. *Signiﬁcantly less than basal condition in
K562 cells, P < 0.01; **signiﬁcantly higher than the corresponding
clone basal condition, P < 0.01.
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Thus, these results are consistent with TRAIL mediating acti-
vation of the receptor apoptotic cascade, a process involvingFig. 4. TRAIL-induced activation of both caspases and Bid and PARP cle
siRNA stable clones #4 and #10 were exposed for 8 and 16 h to 25 ng/ml TRA
addition to the un-cleaved pro-caspases. The results of a representative studalso caspases-9 and -3 which are related to the intrinsic, mito-
chondrial apoptotic pathway.
3.5. TRAIL-induced apoptosis of cells with low levels of RAC3
involves the activation of the mitochondrial pathway
It is well established that TRAIL can induce cell death by
activating mitochondrial-dependent and – independent path-
ways [24]. Therefore, and taking into account the results de-
scribed above (Fig. 4), we analyzed whether the intrinsic/
mitochondrial pathway was also activated by TRAIL as part
of the mechanism of induction of cell death. The mitochon-
drial membrane potential (Dwm) was determined in RAC3-siR-
NA clones and their counterpart K562 wild-type and K562/
con cells after stimulation with TRAIL for 2, 4, 8, 16 and
24 h. Loss of Dwm was evaluated by ﬂow cytometry after stain-
ing with the lipophilic ﬂuorochrome DiOC6 dye. As shown in
Fig. 5A, exposure of RAC3-siRNA clones resulted in a clear
increase in loss of Dwm in RAC3-siRNA clones as compared
to K562/wt and K562/con cells. Again, signiﬁcant diﬀerences
were observed in Dwm depending the level of expression of
RAC3 (Fig. 5A). Other markers of mitochondrial integrity
were then analyzed. Western blot analysis of cytosolic fraction
(S100) revealed a signiﬁcant increase in the amount of mito-
chondrial proteins AIF, cytochrome c and Smac/DIABLO
released from the mitochondria to the cytosol (Fig. 5B);
these proteins were detected in the cytosol early after addition
of TRAIL (i.e., 4 h). Taking together these results indicate
that RAC3 down-regulation sensitizes K562 cells to TRAIL-avage in RAC3-siRNA clones. K562/wt, K562/con cells and RAC3-
IL. The antibodies for caspases recognize the cleaved fragment (CF) in
y are shown; two additional experiments yielded similar results.
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Fig. 5. Exposure to TRAIL induces mitochondrial damage in RAC3-siRNA clones. (A) K562 wild-type, K562/con cells and RAC3-siRNA clones
#4 and #10 were treated with 25 ng/ml TRAIL for 2, 4, 8, 16 and 24 h after which cells were incubated with DioC6 and loss of Dwm was determined
by ﬂow cytometry. Data shown represent the means ± S.D. from three independent experiments. *, **Signiﬁcantly higher than values determined in
K562 after 4 h exposure; P < 0.001 and <0.01, respectively. (B) K562/con cells and RAC3-siRNA stable clones #4 and #10 were exposed for the
indicated time-intervals to 25 ng/ml TRAIL after which proteins were extracted from the cytosolic S-100 fraction, separated by SDS–PAGE gels and
probe with the corresponding antibodies. The results of a representative study are shown; two additional experiments yielded similar results.
G.P. Colo et al. / FEBS Letters 581 (2007) 5075–5081 5079induced apoptosis trough a mechanism involving activation of
both membrane and mitochondrial pathways.
3.6. RAC3 down-regulation diminishes cFLIPL expression and
increases the expression of DR4 and DR5 TRAIL receptors
Recent studies have shown that sensitization of human colon
cancer cells to TRAIL-mediated apoptosis involves a dimin-
ished expression of FLICE inhibitory protein (FLIP) [25], a
protein that interferes with DISC activation and is a potent
inhibitor of the TRAIL-mediated receptor pathway [26].
Moreover, the expression of cFLIP is transcriptionally regu-
lated by NF-jB [27,28]. Attempts were then undertaken to
determine whether modulation of cFLIPL may be involved
in TRAIL-induced lethality in RAC3-siRNA cells. As shown
in Fig. 6A, RAC3-siRNA clones showed a dramatic, RAC3-
dependent reduction in cFLIPL expression compared to
K562/con cells.
It has been also shown that increased sensitivity to TRAIL-
induced cell death in various cell types, including leukemia
cells, may stem from increased expression of TRAIL receptors
[29,30]. Therefore, the levels of membrane-associated death
receptors 4 (DR4) and -5 (DR5) were determined by ﬂow
cytometry. As shown in Fig. 6B, RAC3-siRNA clone #10 cells
displayed a notorious increase (shift to the right) in the amount
of both DR4 (left panel) and DR5 (right panel) associated to
the cell membrane compared to their counterparts K562
wild-type and K562/con cells. Similar results were observed
in RAC3-siRNA clone #4 cells (data not shown).Together, these results suggest that RAC3, by controlling
the basal NF-jB activity, the amount of membrane-associated
DR4 and DR5 and by reducing the levels of the caspase-8 neg-
ative regulator cFLIPL may be playing a key role in modulat-
ing the sensitivity to TRAIL-induced apoptosis in an extrinsic/
receptor-mediated signaling that involves the mitochondrial
apoptotic pathway.4. Discussion
Failure to achieve complete and durable responses from can-
cer chemotherapies is a common clinical problem that limits
the curative potential of anti-cancer drugs in clinical oncology.
The human chronic myeloid leukemia K562 cells are resistant
to several pro-apoptotic drugs eﬀect that has been attributed,
amongst others, to a high expression of the multidrug trans-
porter P-glycoprotein, responsible of the multidrug resistance
(MDR) [31]. In this regard, several chemotherapeutic drugs
are not eﬀective and the development of new speciﬁc strategies
to attack cancer cells is required. Such is the case of apoptosis
induced by TRAIL. In the present study we have found that
human CML K562 cells over-express the p160 family coactiva-
tor RAC3 with levels similar to those observed in mammary
tumor cells [9]. Although not all tumor cells are sensitive to
TRAIL-induced apoptosis and the mechanism underlying
TRAIL-resistance is unclear, we determined that once the
levels of RAC3 are down-regulated, K562 cells, which are
Fig. 6. RAC3-downregulation diminished cFLIPL expression and increased surface expression of DR4 and DR5. (A) Levels of cFLIPL were
determined by Western blot in K562/con cells and RAC3-siRNA clones. (B) Analysis of surface TRAIL receptors DR4 and DR5 by ﬂow cytometry
in K562/wt, K562/con cells and RAC3-siRNA clone #10. Cells were incubated with anti-DR4 and -DR5 speciﬁc antibodies as described in Section 2.
The relative ﬂuorescence intensity (RFI) is indicated for each condition. The results of a representative study are shown; three additional experiments
yielded similar results.
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tive. Consistent with previously described mechanisms of
TRAIL-induced cell death [32], both the membrane and mito-
chondrial pathways appeared rapidly activated upon TRAIL
exposure in K562 cells with RAC3 down-regulation. Our re-
sults indicate that down-regulated RAC3-mediated increased
sensitivity to TRAIL reﬂects changes at diﬀerent levels includ-
ing TRAIL-receptors, which leads to formation of more DISC,
and, importantly, to the release of one of the most critical neg-
ative regulators, cFLIPL. Thereby, our results also suggest that
lack of sensitivity shown by K562 cells to TRAIL may be
strictly correlated to RAC3 over-expression which in turn, as
the present ﬁndings indicate, plays a critical role in maintain-
ing high basal levels of NF-jB. Although we did not analyzed
other leukemic cell lines, these observation contributes to the
knowledge of possible molecular mechanisms that may be in-
volved in other cell lines, including leukemia models, that are
resistant to several drugs or speciﬁc ligand bound receptors.
Accordingly, the levels of RAC3 in other MDR cells deserve
to be investigated.
It has been previously demonstrated that NF-jB inhibits
TNF-a-induced cell death [33]; moreover, constitutive activa-
tion of this transcription factor also prevents TRAIL-induced
apoptosis in renal cancer cells, eﬀect that is reverted by inhib-
iting NF-jB which restored the sensitivity to TRAIL [34]. In
this work, we described for the ﬁrst time that K562 cells ex-
press high levels of the RAC3 coactivator, similar to those ob-
served in human breast tumor T-47D cells, that constitute a
positive control of coactivator over-expression [19]. In addi-
tion, and accordingly to our previous ﬁndings, RAC3
functions as a NF-jB coactivator [6]. Based in these observa-
tions, it is plausible to expect high and/or constitutive
NF-jB activity in these cells. However, whether this is a directeﬀect associated to high levels of RAC3 or it reﬂects regulatory
mechanisms driven by the activity of Bcr-Abl present in these
cells, remains to be determined.
The present ﬁndings indicate that RAC3 down-regulation
aﬀected the basal NF-jB activity, since when we analyzed
NF-jB activity in response to TRAIL, only RAC3 siRNA
clones showed clear activation of NF-jB to values similar to
those present in either K562 wild-type or K562/con cells. These
data may be interpreted either as a consequence of low levels
of TRAIL receptors, which may lead to very modest pro-apop-
totic, and consequently pro-NF-jB eﬀects of TRAIL, or to
high constitutive NF-jB activity related to the presence of
Bcr-Abl. Nonetheless, what our results indicate is that under
RAC3 down-regulation, TRAIL-induced NF-jB activity be-
comes clear and may be explained as the result of lower basal
activity together with higher levels of TRAIL receptors that
enhance the sensitivity to this signal. Finally, the present re-
sults show that RAC3 may represent an important cancer
resistance mediator and has the potential of being explored
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